Inhibitors of Calcineurin

Journal of Pharmacy Practice

Volumn 16, Issue 6, 2003, Pages 414-433

  Holt, Curtis D ^a,b   Ingle, Gordon ^a   Sievers, Theodore M ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse effects; Cyclosporine; Drug interactions; Interleukin 2; Solid organ transplantation; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; BROMOCRIPTINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; CLOTRIMAZOLE; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; GASTROINTESTINAL AGENT; ITRACONAZOLE; KETOCONAZOLE; LOOP DIURETIC AGENT; MACROLIDE; METOCLOPRAMIDE; NEFAZODONE; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROKINETIC AGENT; TACROLIMUS; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; EPSTEIN BARR VIRUS; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEADACHE; HEART TRANSPLANTATION; HEPATITIS C; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MICROEMULSION; NAUSEA; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; PATIENT EDUCATION; REVIEW; SEIZURE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR;

EID: 1642536396     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003260317     Document Type: Review

References (121)

1. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation. 1995;60:1384.
2. Starzl TE, Iwatsuki S, Shaw BW, et al. Liver transplantation in the ciclosporine era. Prog Allergy. 1986;38:366.
3. Thompson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monitor. 1995;17:584.
4. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725.
5. Yee GC. Dosage forms of cyclosporine. Pharmacotherapy. 1991;11:149S.
6. Noble S, Markham A. Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy, and tolerability of a microemulsion-based formulation (Neoral). Drugs. 1995;50:924.
7. Olyaei AJ. Switching between cyclosporin formulations: what are the risks? Drug Safety. 1997;16:366.
8. Kovarik JM, Mueller EA, van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation. 1994;27:658.
9. Kahan BD, Dunn J, Fitts C, et al. The impact of cyclosporin pharmacokinetics on transplant outcome: the potential benefits of Sandimmun Neoral therapy. In: Neoral: A New Formulation of Ciclosporine. New York: World Medical Press; 1994:12.
10. Lindholm A, Kahan B. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205.
11. Trull AK, Tan KKC, Tan L, et al. Absorption of cyclosporin from the conventional and new microemulsion formulation in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol. 1995;39:627.
12. Neumayer HH, Farber L, Haller P, et al. Clinical experience transferring kidney transplant patients from Sandimmun to Sandimmun Neoral: results after 3 months. Clin Nephrol. 1995;43:27S.
13. Neymayer HH, Farber L, Haller P, et al. Conversion from Sandimmun to Sandimmun Neoral: experience in 300 patients after renal transplantation: results after 1 year [abstract]. Nephrol Dial Transplant. 1995;10:1058.
14. Ptachinski RJ, Venkataramanan R, Burckart G. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinetics. 1986;11:107.
15. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinetics. 1993;24:472.
16. Wood AJ. Cyclosporine: pharmacokinetics, metabolism, and drug interactions. Transplant Proc. 1983;15:2409.
17. Burckart GJ. Cyclosporine monitoring and pharmacokinetics in pediatric liver transplant recipients. Transplant Proc. 1985;17:1172.
18. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present and future. Semin Nephrol. 2000;20:108.
19. Lindholm A, Sawe J. Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Ther Drug Monitor. 1995;17:570.
20. Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc. 2000;32(suppl 3A):53S.
21. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs. 2001;15:279.
22. Cole E, Midtvedt K, Johnston A, et al. Recommendations for the implementation of Neoral C 2 monitoring in clinical practice. Transplantation. 2002;73:S19-S22.
23. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002;73(suppl 9):S12.
24. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002;73(suppl 9):S3.
25. Fernandez-Marmiesse A, Hermida J, Tutor JC. Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. Clin Biochem. 2000;33:383.
26. Dunn SP. Neoral monitoring 2 hours post-dose and the pediatric transplant patient. Pediatr Transplant. 2003;7:25.
27. Baraldo M, Francesconi A, Barbone F, et al. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Transplant Int. 2002;15:649.
28. McCoy HG. Laboratory analysis of cyclosporine. Pharmacotherapy. 1991;11:165S.
29. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens. 2002;11:657.
30. Kivisto KT. A review of assay methods for cyclosporin. Clinical implications. Clin Pharmacokinet. 1992;23:173.
31. Andrews DJ, Cramb R. Cyclosporin: revisions in monitoring guidelines and review of current analytical methods Ann Clin Biochem. 2002;39:424.
32. Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 2001;313:241.
33. Morris RG. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring. Ther Drug Monitor. 2000;22:160.
34. Pescovitz MD, Book BK, Pollard SG, et al. An evaluation of the cyclosporine parent-compound-specific whole blood TDx assay. Clin Transplant. 1992;6:43.
35. Wallemacq PE, Alexandre K. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays. Clin Chem. 1999;45:432.
36. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab. 2002;3:275.
37. Abraham MA, Thomas PP, John GT, et al. Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc. 2003;35:215.
38. Delgado JF, Sanchez V, De La Calzada CS, et al. Impact of diltiazem administration and cyclosporine levels on the incidence of acute rejection in heart transplant patients. Transplant Int. 2003;16:676-680.
39. Rossi SJ. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety. 1993;9:104.
40. Kreis H. New strategies to reduce nephrotoxicity. Transplantation. 2001;72(suppl 12):S99.
41. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23:465.
42. Kim W, La BJ, Lee S, et al. A case of early onset cyclosporine-induced hemolytic uremic syndrome resulting in renal graft loss. Clin Nephrol. 2003;59:148.
43. Abraham KA, Little MA, Dorman AM, Walshe JJ. Hemolyticuremic syndrome in association with both cyclosporine and tacrolimus. Transplant Int. 2000;13:443.
44. Heering P, Degenhardt S, Grabensee B. Tubular dysfunction following kidney transplantation. Nephron. 1996;74(3):501-511.
45. Vannini SD, Mazzola BL, Rodoni L, et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transplant Int. 1999;12:244.
46. Chowdhury S, Kode RK, Ranganna K, et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. Transplant Proc. 2001;33:1057.
47. McDonald SP, Russ GR. Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients. Kidney Int. 2002;6:2259.
48. Flechner SM, Goldfarb D, Modlin C. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070.
49. Jorkasky DK, Audet P, Shusterman N, et al. Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. Am J Kidney Dis. 1992;19:567.
50. Pollak R, Knight R, Mozes MF, et al. A trial of the prostaglandin El analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction. Am J Kidney Dis. 1992;20:336.
51. Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy. 1991;11:119.
52. Hood KA. Drug-induced gingival hyperplasia in transplant recipients. Prog Transplant. 2002;12:17.
53. Hernandez D, Alvarez A, Torres A, et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc. 2003;35:1727.
54. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246:339.
55. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol. 1999;39:995.
56. Borel JF. Pharmacology of cyclosporine (Sandimmun). IV. Pharmacological properties in vivo. Pharmacol Rev. 1990;41:259.
57. Pollard S, Nashan B, Johnston A, et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther. 2003;25:1654.
58. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Exp Rev Clin Med. 2000;21:1.
59. Weimer R, Melk A, Daniel V, et al. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol 2000;61:884.
60. Miyagi M, Muramatsu M, Ishikawa Y, et al. Comparison of the therapeutic effects between CsA and FK506 on chronic renal allograft injury and TGF-beta expression. Transplant Proc. 2002;34:1589.
61. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404.
62. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813.
63. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62:1481-1502.
64. van Gelder T. Drug interactions with tacrolimus. Drug Safety. 2002;25:707.
65. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985.
66. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 2001;21:778.
67. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Safety 1997;16:267.
68. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care. 2001;7:384.
69. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46:746.
70. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transplant. 2002;8(10 suppl 1):S19.
71. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;27:331.
72. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant. 2001;5:359.
73. Kelly DA. Strategies for optimizing immunosuppression in adolescent transplant recipients: a focus on liver transplantation. Paediatr Drugs. 2003;5:177.
74. Dhawan A, Mack DR, Langnas AN. Immunosuppressive drugs and hypertrophic cardiomyopathy. Lancet. 1995;345:1644.
75. Staatz CE, Taylor PJ, Tett SE. Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. Ther Drug Monitor. 2002;24:607.
76. O'Grady JG, Burroughs A, Hardy P, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119.
77. Timmermann W, Erhard J, Lange R, et al. A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation. Transplant Proc. 2002;34:1516.
78. Sher LS, Cosenza CA, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation. 1997;64:258-263.
79. Levy GA. Neoral is superior to FK 506 in liver transplantation. Transplant Proc. 1998;30:1812.
80. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation. 1998;66:493.
81. Mueller AR, Platz K, Willimski C, et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. Transplant Proc. 2001;33:1347-1349.
82. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 1998;65:1044.
83. Ghobrial RM, Steadman R, Gombein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384-393.
84. Guckelberger O, Bechstein WO, Neuhaus R, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant. 1997;11:60-65.
85. Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation. 1997;64:938.
86. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation. 2003;75:186.
87. Neau-Cransac M, Morel D, Bernard PH, et al. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant. 2002;16:368.
88. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int. 2000;13:313.
89. Starzl T, Fung J, Jordan M, et al. Kidney transplantation under FK506. JAMA. 1990;264:63.
90. Shapiro R, Jordan M, Scantlebury V, et al. FK 505 in clinical kidney transplantation. Transplant Proc. 1991;23:3065.
91. Vicenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open label trial of FK506 for primary kidney transplantation. Transplantation. 1996;61:1576.
92. Shapiro R, Jordan ML, Scantlebury V, et al. A prospective randomized trial of FK506 based immunosuppression after renal transplantation. Transplantation. 1995;59:485.
93. Shapiro R, Jordan ML, Scantlebury V, et al. Randomized trial of FK506/prednisone vs FK506/azathioprine/prednisone after renal transplantation: a preliminary report. Transplant Proc. 1993;25:669.
94. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation. 1997;64:436.
95. Mayer AD. Four-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc. 1999;31(suppl 7A):27S.
96. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997;63:977.
97. Jensik SC. Tacrolimus (FK506) in kidney transplantation: three year survival results of the multicenter, randomized, comparative trial. Transplant Proc. 1998;30:1216.
98. Shapiro R, Jordan ML, Scantlebury V, et al. A prospective, randomized trail of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999;67:411.
99. Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection-five year experience. Transplantation. 1997;63:223.
100. Dew MA, Harris RC, Simmons RG, Roth LH, Armitage JM, Griffith BP. Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. Transplant Proc. 1991;23:3061.
101. Steinbüchel NV, Limm H, Leopold C, Carr D. Assessment of health related quality of life in patients after heart transplantation under therapy with tacrolimus or cyclosporine. Transplant Int. 2000;13(suppl 1):S609.
102. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18:336.
103. Reichart B, Meiser B, Viganáo M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant. 1998;17:775.
104. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant. 1998;17:782.
105. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant. 1999;18:143.
106. Klauss V, König A, Spes C, et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol. 2000;85:266.
107. Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant. 1997;16:1001.
108. Baran DA, Segura L, Kushwaha S, et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant. 2001;20:59.
109. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant. 1999;18:448.
110. Mentzer RJ, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US Multicenter FK506 Study Group. Transplantation. 1998;65:109.
111. De Bonis M, Reynolds L, Barros J, Madden BP. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg. 2001;19:690.
112. Meiser BM, Überfuhr P, Fuchs A, et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant. 1997;16:795.
113. Yamani MH, Starling RC, Pelegrin D, et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant. 2000;19:337.
114. Mathieu P, Carrier M, White M, et al. Conversion of cyclosporine A to tacrolimus following heart transplantation. Can J Cardiol. 1999;15(11):1229.
115. Keenan RJ, Dauber JH, Iacono AT, Zaldonis BP, Griffith BP. Long term followup-clinical trial of tacrolimus versus cyclosporine for lung transplantation [abstract 61]. J Heart Lung Transplant. 1998;17:58.
116. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant. 2001;20:511.
117. Reichenspurner H, Kur F, Treede H, et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation. 1999;68:67.
118. Horning NR, Lynch JP, Sundaresan SR, Patterson GA, Trulock EP. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant. 1998;17:761.
119. Klepetko W, Estenne M, Glanville A, et al. A multicenter study to assess outcome following a switch in the primary immunosuppressant from cyclosporin (CYA) to tacrolimus (TAC) in lung recipients [abstract]. J Heart Lung Transplant. 2001;20(2):208.
120. Wiebe K, Harringer W, Franke U, et al. FK506 rescue therapy in lung transplantation. Transplant Proc. 1998;30:1508.
121. Lipson DA, Palevsky HI, Kotloff RM, Edelman J. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc. 1998;30:1505.